Cellular senescence as a target in cancer control

Current Cancer Therapy Reviews

Volumn 3, Issue 1, 2007, Pages 7-15

  Carnero, Amancio ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Cellular senescence; Immortality; Senescence targets; Telomere shortening

Indexed keywords

6 ANILINO 5,8 QUINOLINEQUINONE; APHIDICOLIN; BROXURIDINE; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; FLUOROURACIL; HYDROXYUREA; MITOGENIC AGENT; PACLITAXEL; PROTEIN P14ARF; PROTEIN P16; PROTEIN P21; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE INHIBITOR; VINCRISTINE;

APOPTOSIS; CANCER CONTROL; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CELL AGING; CELL CULTURE; CELL DIVISION; CELL GROWTH; CELL IMMORTALIZATION; CELL STIMULATION; CELL VIABILITY; CYTOTOXICITY; DNA DAMAGE; DRUG EFFICACY; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SOMATIC CELL; STRESS; TARGET CELL; UNSPECIFIED SIDE EFFECT;

EID: 34047159224     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339407780126629     Document Type: Review

References (85)

1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Rubin, H. Cell aging in vivo and in vitro. Mech. Ageing Dev 1997; 98: 1-35.
4. Untergasser G, Koch HB, Menssen A, Hermeking H. Characterization of epithelial senescence by serial analysis of gene expression: identification of genes potentially involved in prostate cancer. Cancer Res 2002; 62: 6255-62.
5. Mason DX, Jackson TJ, Lin AW. Molecular signature of oncogenic ras-induced senescence. Oncogene, 2004; 23: 9238-46.
6. Schwarze SR, Fu VX, Desotelle JA, Kenowski ML, Jarrard DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005; 7: 816-23.
7. Zhang H, Pan KH, Cohen SN. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci USA 2003; 100: 3251-6.
8. Shay JW, Roninson IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 2004; 23: 2919-33.
9. Thomas E, Al-Baker E, Dropcova S, et al. Different kinetics of senescence in human fibroblasts and peritoneal mesothelial cells. Exp Cell Res 1997; 236: 355-358.
10. Rubin H, The disparity between human cell senescence in vitro and lifelong replication in vivo. Nat Biotech 2002; 20: 675-81.
11. Wright WE, Shay JW. Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism? Trends Cell Biol 1995; 5: 293-297.
12. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973; 41: 181-190.
13. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426: 194-8.
14. Narita M, Nunez S, Heard E, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003; 113: 703-16.
15. Wynford-Thomas D. p53: Guardian of cellular senescence. J Pathol. 1996; 180: 118-121.
16. Bond J, Haughton M, Blaydes J, et al. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene 1996; 13: 2097-2104.
17. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-38.
18. Garkavtsev I, Riabowol K. Extension of the replicative lifespan of human diploid fibroblasts by inhibition of the p33ING1 candidate tumour suppressor. Mol Cell Biol 1997; 17: 2014-2019.
19. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 1999; 18: 7637-43.
20. Blaydes JP, Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 1998; 16: 3317-3322.
21. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91: 649-659.
22. Carnero A, Hudson JD, Price CM. and Beach DB. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nature Cell Biol 2000; 2: 148-155.
23. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev 2000; 14: 2015-27.
24. Pantoja C, Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999; 18: 4974-82.
25. Carnero A, Beach DH. Absence of p21WAF1 cooperates with cmyc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene 2004; 23: 6006-11.
26. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997; 277: 831-4.
27. Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005; 25: 7423-31.
28. Carnero A. Cell cycle and cell-cycle checkpoints. In The Encyclopedia of Respiratory Medicine. Ed Elsevier Ltd ISBN (Set): 0-12-438360-2 Editors: Geoffrey J. Laurent and Steven D. Shapiro© 2006; pp 347-355.
29. Wazer DE, Liu X-L, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci USA 1995; 92: 3687-3691.
30. Mulligan G, Jacks T. The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 1998; 14: 223-9.
31. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998; 227: 43-55.
32. Palmero I, McConnell B, Parry D, et al. Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma, gene status. Oncogene 1997; 15: 495-503.
33. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045-11049.
34. Krimpenfort P, Quon KC, Mooi WJ, Loonstra A, Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83-6.
35. Sharpless NE, Bardeesy N, Lee KH, et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001; 413: 86-91.
36. Amati B, Alevizopoulos Y, Vlach J. Myc and the cell cycle. Front Biosci 1998; 3: D250-268.
37. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. Myc activates telomerase. Genes Dev 1998; 12: 1769-74.
38. Gil J, Kerai P, Lleonart M, et al. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res 2005; 65: 2179-85.
39. Serrano M, Lin AW, McCurrach ME, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1998; 88: 593-602.
40. Lee AC, Fenster BE, Ito H, et al. Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 1999; 274: 7936-40.
41. Wei S, Wei S, Sedivy JM. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res 1999; 59: 1539-43.
42. Zhu J, Woods D, McMahon M., Bishop JM. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev 1998; 12: 2997-3007.
43. Lin AW, Barradas M, Stone JC, et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signalling. Genes Dev 1998; 12: 3008-19.
44. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998; 395: 125-6.
45. Michaloglou C, Vredeveld LC, Soengas MS, et al. Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436: 720-4.
46. Braig M, Lee S, Loddenkemper C, et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005; 436: 660-5.
47. Collado M, Gil J, Efeyan A, et al. Tumour biology: senescence in premalignant tumours. Nature. 2005; 436: 642.
48. Lazzerini Denchi E, Attwooll C, Pasini D, Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005; 25: 2660-72.
49. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436: 725-30.
50. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63: 2705-15.
51. Carnero A, Link W, Martinez JF, et al. Cellular Senescence and Cancer. Res Adv Cancer 2003; 3: 183-198.
52. Pereira-Smith OM, Smith JR. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc Natl Acad Sci USA 1988; 85: 6042-6046.
53. McConnell BB, Starborg M, Brookes S, Peters G. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998; 8: 351-4.
54. Carnero A, Hudson JD, Hannon GJ, Beach DH. Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res 2000; 28: 2234-41.
55. Carnero A. Targeting the cell cycle for cancer therapy. British J Cancer 2002; 87: 129-130.
56. Ball KL, Lain S, Fahraeus R, Smythe C, Lane DP. Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Curr Biol 1997; 7: 71-80.
57. Schmitt CA, Fridman JS, Yang M, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-46.
58. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
59. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307-15.
60. Roninson IB. Tumor senescence as a determinant of drug response in vivo. Drug Resist Updat 2002; 5: 204-8.
61. te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62: 1876-83.
62. Maloney K W, McGavran L, Odom LF, Hunger SP. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999; 93: 2380-2385.
63. Carter T L, Watt PM, Kumar R, et al. Hemizygous p16(INK4A) deletion in pediatric acute lymphoblastic leukemia predicts independent risk of relapse. Blood 2001; 97: 572-574.
64. Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 4677-4685.
65. Chen QM. Replicative senescence and oxidant-induced premature senescence. Beyond the control of cell cycle checkpoints. Ann N Y Acad Sci 2000; 908: 111-25.
66. Chang BD, Broude EV, Dokmanovic M, et al, A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 1999; 59: 3761-7.
67. Wang X, Wong SC, Pan J, et al. Evidence of cisplatin-induced senescent-like growth arrest in nasopharyngeal carcinoma cells. Cancer Res 1998; 58: 5019-22.
68. Yeo EJ, Hwang YC, Kang, CM, et al. Senescence- like changes induced by hydroxyurea in human diploid fibroblasts. Exp Gerontol 2000; 5: 553-71.
69. Michishita E, Nakabayashi K, Suzuki T, et al. 5-Bromodeoxy-uridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J Biochem 1999; 126: 1052-9.
70. Chang BD, Xuan Y, Broude EV, et al. Role of p53 and p21wafl/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 1999; 18: 4808-18.
71. Elmore LW, Rehder CW, Di X, et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J Biol Chem 2002; 277: 35509-15.
72. Gire V, Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004; 23: 2554-63.
73. Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A, Ferbeyre G. DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. Mol Biol Cell 2006; 17: 1583-92.
74. Lodygin D, Menssen A, Hermeking HR. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest 2002; 110: 1717-27.
75. Kondoh H, Lleonart ME, Gil J, et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-85.
76. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-2015.
77. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999; 5: 1164-1170.
78. Blackburn, E. Telomere states and cell fates. Nature 2000; 408: 53-56.
79. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
80. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-712.
81. Vulliamy TJ, Marrone, A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001; 413: 432-435.
82. Marciniak R, Guarente L. Testing telomerase. Nature 2001; 413: 370-372.
83. Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer? Nature Med 2000; 6: 852-855.
84. Holt SE, Wright WE, Shay JW. Multiple pathways for the regulation of telomerase activity. Eur J Cancer 1997; 33: 761-766.
85. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999; 13: 2388-2399.